Organon (OGN) and Samsung Bioepis said Tuesday that the US Food and Drug Administration has designated Hadlima high and low concentration autoinjectors and high-concentration prefilled syringe as interchangeable biosimilars to AbbVie's (ABBV) Humira.
The FDA previously granted interchangeability designation to Hadlima low-concentration prefilled syringe and single-dose vial in June 2024, the company said.
An interchangeability designation enables a pharmacist to substitute the reference product with a biosimilar without the need to consult the prescriber, the company said.
Shares of Organon were 5% higher in recent trading.
Price: 9.11, Change: +0.42, Percent Change: +4.78
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.